Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent <i>In Vivo</i> Anti-tumor Immune Activity-Reference-Cited by-同舟云学术

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

Published:2024-03-11 Issue:6 Volume:67 Page:4977-4997
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Liu Liu¹²,Zhang Honghan¹,Hou Jie¹,Zhang Yuying¹³,Wang Luosen¹,Wang Shijun¹,Yao Zhiying¹,Xie Tao¹,Wen Xiaoan¹²^ORCID,Xu Qinglong¹²^ORCID,Dai Liang¹²^ORCID,Feng Zhiqi¹²,Zhang Pu⁴,Wu Yaojun⁴,Sun Hongbin¹²^ORCID,Liu Jun¹³,Yuan Haoliang¹²^ORCID

Affiliation:

1. Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

2. Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China

3. New Drug Screening Center, China Pharmaceutical University, Nanjing 210009, China

4. Jiangsu Flag Chemical Industry Co., Ltd., Nanjing 211500, China

Funder

Natural Science Foundation of Chongqing Municipality

China Postdoctoral Science Foundation

Natural Science Foundation of Jiangsu Province

National Natural Science Foundation of China

Jiangsu Funding Program for Excellent Postdoctoral Talen

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00102

Reference29 articles.

1. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

2. Immune checkpoint signaling and cancer immunotherapy

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

4. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma